90. Kongreß pp 948-960 | Cite as

Klinische Pharmakologie II

  • K. Roosen
  • P. Meusers
  • W. Havers
  • J. Schaaf
  • W. Londong
  • V. Londong
  • K. Spitzer
  • H. Bechtold
  • L. S. Weilemann
  • J. Lorenz
  • K. Andrassy
  • D. Trenk
  • T. Meinertz
  • E. Jähnchen
  • C. Zekorn
  • P. Reetz
  • G. Mikus
  • M. Eichelbaum
  • E. Fritschka
  • Th. Lenz
  • A. Distler
  • Th. Philipp
  • G. Achtert
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für Innere Medizin book series (VDGINNERE, volume 90)

Zusammenfassung

1963 beschrieb Ommaya ein subkutanes Plastikreservoir, das nach Implantation unter die Kopfhaut einen direkten, sterilen, wiederholbaren Zugang zum Ventrikelliquor ermöglichte. Nach okzipitaler Bohrlochtrepanation des Schädels wurde ein Siliconkatheter in das Hinterhorn des Seitenventrikels eingeführt und an das Reservoir angeschlossen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Blasberg RG, Patlak CS, Shapiro WR (1977) Distribution of the methotrexate in the CSF an brain after interventricular administration. Cancer Treat Rep 61: 633–641PubMedGoogle Scholar
  2. Bleyer WA, Poplack DG, Simon RM (1978) “Concentrations x Time” Methotrexate via a subcutaneous reservoir. Blood 51: 835–842PubMedGoogle Scholar
  3. Bleyer WA, Poplack DG (1979) Intraventricular versus intralumbar methotrexate for centralnervous-system leukemica. Med Pediatr Oncol 6: 207PubMedCrossRefGoogle Scholar
  4. Bleyer WA (1983) Central-nervous-system leukemia. In: Gunz FV, Henderson ES (eds) Leukemia. Grune and Stratton, New York London Paris San Diego San Franzisko Sao Paulo Sydney Tokyo Toronto, pp 865–911Google Scholar
  5. Bresnan MJ (1972) Leucencephalopathy following combined irradiation and intraventricular methotrexate-therapy. Trans Am Neurol Assoc: 204–206Google Scholar
  6. Galicich JH, Guido LJ (1974) Ommaya device in carcinomatous and leucemic meningitis. Clin North Am 915–922Google Scholar
  7. Green DM, West CR, Brecher ML et al. (1982) The use of subcutaneous CSF reservoir. Am J Pediatr Hematol Oncol 147–154Google Scholar
  8. Kaplan RS, Wiernik PH (1982) Neurotoxicity of antineoplastic drugs. Semin Oncol 1: 103–130Google Scholar
  9. Lobato RD, Madrid JL, Fatela LV et al. (1983) Intraventricular morphine for control of pain in terminal cancer patients. J Neurosurg 59: 633–640Google Scholar
  10. Ommaya AK (1963) Lancet 2: 983CrossRefGoogle Scholar
  11. Possner J (1973) Reservoirs for intraventricular chemotherapy. N Engl J Med 212Google Scholar
  12. Ratcheson RA, Ommaya AK (1968) Experience with the subcutaneous CSF reservoir. N Engl J Med 279: 1025–1031PubMedCrossRefGoogle Scholar
  13. Roosen K, Havers W, Schaaf J (1982) Indications and experiences with the Ommaya-reservoir. In: Voth D, Gutjahr P, Langmaid C (eds) Tumours of the central nervous system in infancy and childhood. Springer, Berlin Heidelberg New York, pp 265–269CrossRefGoogle Scholar
  14. Rubin RC, Ommaya AK, Henderson ES et al. (1966) CSF perfusion for CNS neoplasms. Neurology 16: 580–592CrossRefGoogle Scholar
  15. Shapiro WR, Young DF, Mehta BM (1975) Methotrexate in CSF after intravenous, ventricular and lumbar injections. N Engl J Med 293: 161–165PubMedCrossRefGoogle Scholar
  16. Shapiro RW, Posner JB, Ushio Y et al. (1977) Treatment of meningeal neoplasms. Cancer Treat Rep 61: 733–743PubMedGoogle Scholar
  17. Spiers ASD, Booth AE (1973) Reservoir for intraventricular chemotherapy. Lancet 2: 1263CrossRefGoogle Scholar
  18. Spiers ASD, Booth AE, Firth GL (1978) Subcutaneous cerebrospinal fluid reservoir in patients with akute leucaemia. J Haematol 20: 289–296Google Scholar
  19. Suger O, Bailey OT (1974) Subcutaneous reaction to silicone in ventriculoperitoneal shunt. J Neurosurg 41: 367–371CrossRefGoogle Scholar
  20. De Vries EGE, Mulder NH, Houwen B, Haaxma-Reiche H (1982) Combinations chemotherapy for acute lymphocytie leukaemica. Blut 44: 151–158PubMedCrossRefGoogle Scholar
  21. 1.
    Neu H (1983) Adverse effects of new cephalosporins. Ann Intern Med 98: 415–416Google Scholar
  22. 2.
    Schwigon CD, Barkow D (1982) Blutgerinnungsstörungen unter Cefoperazon and Lamoxactam. Diagnostik Intensivtherapie 7: 221–225Google Scholar
  23. 3.
    Bell RG (1978) Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K-epoxide cycle. Fed Proc 37: 2599–2604PubMedGoogle Scholar
  24. 4.
    Shearer M, McBurney A, Breckenridge A, Barkhan P (1977) Effect of warfarin on the metabolism of phylloquinone (vitamin Kt): Dose-response relationship in man. Clin Sci Mol Med 52: 621–630Google Scholar
  25. 5.
    Bechtold H, Trenk D, Meinertz T, Rowland M, Jähnchen E (1983) Cyclic interconversion of vitamin Ki and vitamin Ki 2,3-epoxide in man. Br J Clin Pharmacol 16: 683–689PubMedCrossRefGoogle Scholar
  26. 6.
    Hildebrandt EF, Suttie JW (1983) The effects of salicylate on enzymes of vitamin K metabolism. J Pharm Pharmacol 35: 421–426PubMedCrossRefGoogle Scholar
  27. 7.
    Bechtold H, Trenk D, Meinertz T, Jähnchen E (1984) Effect of salicylate on the vitamin Ki-metabolism in man. Naunyn-Schmiedebergs Arch Pharmacol (Suppl) 325: R 12Google Scholar
  28. 8.
    Bechtold H, Trenk D, Jähnchen E, Meinertz T (1983) Plasma vitamin Ki 2,3-epoxide as diagnostic aid to detect surreptitious ingestion of oral anticoagulant drugs. Lancet 1: 595–597Google Scholar
  29. 9.
    Bechtold H, Klein F, Trenk D, Jähnchen E (1984) Improved method for quantitative analysis of vitamin K1 and vitamin Ki 2,3-epoxide in human plasma by electron-capture gas-liquid capillary chromatography. J Chromatogr 306: 333–337PubMedGoogle Scholar
  30. 1.
    Schwietzer G, Distler A, Reeck S, Thiede HM, Philipp T (1983) Hypotensive action of calcium antagonists as related to plasma noradrenaline and reactivity to noradrenaline. J Hypertension (Suppl 2 ): 102–104Google Scholar
  31. 2.
    Breemen van C, Mangel A, Fahim M, Meisheri K (1982) Selectivity of calcium antagonistic action in vascular smooth muscle. Am J Cardiol 49: 507–510PubMedCrossRefGoogle Scholar
  32. 3.
    Zwieten van PA, Meel van JC, Timmermans PB (1983) Pharmacology of calcium entry blockers: Interaction with vascular alphaadrenoceptors. Hypertension 5: II8—II17Google Scholar
  33. 4.
    Steel RGD, Torrie JH (ed) (1960) Principles and procedures of statistics. McGraw-Hill, New York Toronto London, pp 433–453Google Scholar
  34. 5.
    Vierhapper H, Waldhäusl W (1982) Reduced pressure effect of angiotensin II and of noradrenaline in normal man following the oral administration of the calcium-antagonist nifedipine. Eur J Clin Invest 12: 263–267PubMedCrossRefGoogle Scholar
  35. 6.
    Barnathan ES, Addonizio VP, Shattil SJ (1982) Interaction of verapamil with human platelet alpha-adrenergic receptors. Am J Physiol 242: H19–23PubMedGoogle Scholar
  36. 7.
    Motulsky HJ, Snavely MD, Hughes RJ, Insel PA (1983) Interaction of verapamil and other calcium channel blockers with alpha-and alpha2-adrenergic receptorsGoogle Scholar
  37. 8.
    Hollenberg MD (1978) Hormone receptor interactions at the cell membrane. Pharmacol Rev 30: 393–410PubMedGoogle Scholar
  38. 9.
    VanHoutte PM, Rimele TJ (1983) Calcium and alpha-adrenoceptors in activation of vascular smooth muscle. J Cardiovasc Pharmacol (Suppl3) 4: 5280–5286Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • K. Roosen
    • 1
  • P. Meusers
    • 2
  • W. Havers
    • 3
  • J. Schaaf
    • 1
  • W. Londong
    • 4
  • V. Londong
    • 4
  • K. Spitzer
    • 4
  • H. Bechtold
    • 5
  • L. S. Weilemann
    • 5
  • J. Lorenz
    • 5
  • K. Andrassy
    • 6
  • D. Trenk
    • 7
  • T. Meinertz
    • 8
  • E. Jähnchen
    • 7
  • C. Zekorn
    • 9
  • P. Reetz
    • 9
  • G. Mikus
    • 9
  • M. Eichelbaum
    • 9
  • E. Fritschka
    • 11
  • Th. Lenz
    • 10
  • A. Distler
    • 10
  • Th. Philipp
    • 10
  • G. Achtert
    • 11
  1. 1.Neurochirurg. Klinikdes Universitätsklinikums Essen GHSDeutschland
  2. 2.Abt. für Hämatologie an der Med. Klinikdes Universitätsklinikums Essen GHSDeutschland
  3. 3.Kinderklinikdes Universitätsklinikums Essen GHSDeutschland
  4. 4.MünchenDeutschland
  5. 5.II. Med. Klinik und PoliklinikUniversität MainzDeutschland
  6. 6.Klinikum der Universität HeidelbergDeutschland
  7. 7.PharmakologInstitut der Universität MainzDeutschland
  8. 8.II. Med. Klinik und PoliklinikUniversität MainzDeutschland
  9. 9.Med. Klinik BonnDeutschland
  10. 10.Med. Klinik und Poliklinik, Klinikum SteglitzFreie Universität BerlinDeutschland
  11. 11.Bonn/HannoverDeutschland

Personalised recommendations